HLB's stock futures surged, meeting the requirements for an expanded price limit. At the same time, the company is raising funds by issuing 30 billion won worth of convertible bonds (CB) to finance new drug development and commercialization, drawing keen market attention.

According to the Korea Exchange, HLB stock futures rose 10% from the base price at 10:18:29 a.m. on the 10th, reaching the threshold for a 'Stage 2 price limit expansion.' Accordingly, starting five minutes later at 10:23:29 a.m., the upward price limit was widened from the previous stage to 20%. If the executed price rises 20% above the base price, the limit could be further expanded to 30% five minutes later. The exchange noted that real-time price limits do not apply after a price limit expansion, and advised investors to exercise caution as prices may temporarily fluctuate significantly due to market orders submitted before the expansion.

Another focus of the market on this day was HLB's large-scale fundraising. HLB held a board meeting on the 5th and decided to issue a total of 30 billion won worth of '44th Unsecured Private Convertible Bonds.' All of the raised funds will be used as operating capital for research and development, clinical funding, and commercialization costs.

Looking at the issuance terms, the convertible bonds have a coupon rate of 1% per annum and a yield to maturity of 4% per annum, with a maturity date of August 19, 2029. The conversion price was set at 33,361 won per share, and if all bonds are converted into shares, 899,253 new shares (approximately 0.68% of the total currently issued shares) will be issued. In the event of a conversion price adjustment due to a decline in market price, the minimum adjusted price was set at 23,353 won. The conversion claim period runs from August 19, 2027, to July 19, 2029.

The payment date is August 19, and the main subscribers are BNK Investment Securities (24.5 billion won), Cactus Oasis No. 3 Investment Fund (4 billion won), and Jin Yang-gon (1.5 billion won). Notably, a call option allowing Jin Yang-gon to purchase some or all of 7% of the total electronic registration amount underwritten by BNK Investment Securities will be granted through a separate contract. Additionally, bondholders may exercise their early redemption rights starting February 19, 2028, subject to certain conditions.

With this convertible bond issuance, the combined balance of HLB's outstanding equity-related bonds totals 315.606 billion won. The number of shares eligible for conversion or exercise stands at 6,900,151 shares, representing 5.18% of the total issued shares.

The market is closely watching the expansion of the stock futures price limit and the fundraising structure for new drug development. However, some point out that convertible bonds could become a factor for a potential increase in the number of shares (dilution) depending on future stock prices and conversion price adjustments, making it necessary to carefully review the actual timing and scale of conversion.

[※ This article is for informational purposes only and does not recommend the purchase or sale of any specific stock. Investment decisions and responsibilities lie with the investor. This article was written with AI assistance.]